Clinical laboratory International (CLI)
The leading international magazine for Clinical laboratory Equipment for everyone in the in vitro diagnostics field and related disciplines.
https://clinlabint.com/wp-content/uploads/sites/2/2023/11/Nuevo-edificio-Certest-2.jpg
1280
1920
panglobal
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png
panglobal2023-11-27 11:48:192023-11-28 09:28:08Certest completes the expansion of its new facilities
The growing spectrum of neural autoantibodies and associated syndromes
, /in Featured Articles /by panglobalBy Dr Jacqueline Gosink Autoimmune neurology is a rapidly growing field driven by the ongoing discovery of novel neural autoantibodies associated with recognizable clinical syndromes. These diseases can affect the central, peripheral and autonomic nervous systems and may co-occur with cancer. Today’s testing landscape encompasses more than 60 neural autoantibodies targeting different intracellular proteins, receptors […]
Tumour markers in lung cancer: modelling strategies for interpretation of tumour marker changes and potential clinical applications
, /in Featured Articles /by panglobalBy Dr F. van Delft, Dr M. Schuurbiers, Dr van den Heuvel and Dr H. van Rossum The development of immunotherapy and other targeted therapies has given rise to significant improvements in the treatment of non-small cell lung cancer. However, some patients do not benefit from these therapies and it is, therefore, important for a […]
The Man Van: catching prostate cancer early
, /in Featured Articles /by panglobalWe all know that detecting cancer early is the key to obtaining the best treatment outcomes. However, how do you do this when some sectors of the population struggle to access healthcare and does point-of care testing make it possible to take health screening to the people who need it? CLI caught up with Professor […]
Improving equity of diagnosis of ovarian cancer
, /in Featured Articles /by panglobalAlthough the prevalence of ovarian cancer is fairly low, it is often asymptomatic until after metastasis, resulting in it being the fourth leading cause of cancer death in females in the USA. The development of biomarker screening tests for ovarian cancer has been challenging and the situation is still not satisfactory. Additionally, the tests that […]